Skip to search formSkip to main contentSkip to account menu

Sulfatinib

An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

HMPL-012
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
6037Background: Sulfatinib is an oral tyrosine kinase inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR… 
2017
2017
Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases
Both vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) singling pathways can… 
2014
2014
First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
2615 Background: Sulfatinib is a highly selective oral small molecule tyrosine dual inhibitor of vascular endothelial growth… 
2012
2012
First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
3040 Background: Sulfatinib is a highly selective oral small molecule tyrosine dual inhibitor of vascular endothelial growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)